Bowel Cancer Screening
Alpha Laboratories has been at the forefront of faecal testing in the UK for over 20 years.
This was initially as the market leader for guaiac based faecal occult blood testing. We won tenders for bowel screening in all four UK countries, as each launched its own screening programme.
Continuing to provide leading edge products, Alpha Laboratories introduced the first faecal immunochemical testing (FIT) method for screening, initially being awarded the contract for quantitative FIT as the front line test in the Scottish Bowel Screening Programme. Tender wins for FIT screening in Wales and Northern Ireland followed.
Early Identification of Bowel Disease Improves Patient Outcomes
Studies suggest that over 90% of bowel cancer patients would survive if they were identified and treated in the early stages of the disease. Many cancers start as small growths on the lining of the gut called “Polyps”. The formation of these polyps becomes more common as we get older, and not all polyps will develop into cancerous growths. Patients who have developed polyps can be identified as these tend to bleed into the gut and this blood can be found in the faeces. The polyps, if potentially cancerous, can easily be removed during a colonoscopy.
FIT for Bowel Cancer Screening: The Benefits
Detects intact haemoglobin and early degradation products using monoclonal/polyclonal antibodies to globin
Greater clinical sensitivity
Detects more adenomas
Easier to collect the faecal sample using a method that is more acceptable to people invited for screening, promoting increased uptake
No diet or drug interferences
More specific for lower GI bleeding
Easier analysis using a single sample tested on automated systems
Advocated in many publications and most new guidelines
Users can select cut off for age, gender, colonoscopy resources
NHS Bowel Cancer Screening: http://www.cancerscreening.nhs.uk/bowel/